Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 23 days ago
Share
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
84 patients around the world
Available in
Chile, United States
The study duration per participant will be up to 116 weeks.
Sanofi
1
Research sites
84
Patients around the world
This study is for people with
Hidradenitis suppurativa
Requirements for the patient
To 70 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
Sites
Clínica Dermacross S.A. - Vitacura - Santiago
Recruiting
Consult
View site
Av. Manquehue Norte 2051 C, Vitacura, Metropolitana, 7640881
View site
Consult
See details
Contact us
Contact us
Sponsor
Sanofi
Conditions
Hidradenitis suppurativa
Requirements
To 70 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT06118099
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent